BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Federal Trade Commission
Chubb
US Department of Justice
Express Scripts
Merck
Julphar
Harvard Business School
Covington
Healthtrust

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,635,485

« Back to Dashboard

Which drugs does patent 5,635,485 protect, and when does it expire?

Patent 5,635,485 protects KETEK and is included in one NDA.

This patent has sixty-two patent family members in thirty-nine countries.
Summary for Patent: 5,635,485
Title: Erythromycin compounds
Abstract:An erythromycin compound of Formula I or its non-toxic acid addition salt having antibiotic activity.
Inventor(s): Agouridas; Constantin (Nogent sur Maine, FR), Chantot; Jean-Francois (Nogent sur Maine, FR), Denis; Alexis (Paris, FR), D'Ambrieres; Solange G. (Paris, FR), Martret; Odile L. (Paris, FR)
Assignee: Roussel Uclaf (FR)
Application Number:08/426,067
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 5,635,485

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sanofi Aventis Us KETEK telithromycin TABLET;ORAL 021144-002 Feb 9, 2005 DISCN No No ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER. ➤ Subscribe
Sanofi Aventis Us KETEK telithromycin TABLET;ORAL 021144-001 Apr 1, 2004 DISCN No No ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER. ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,635,485

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France94 05368May 03, 1994

Non-Orange Book US Patents Family Members for Patent 5,635,485

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,100,404 Erythromycin compounds ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,635,485

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Israel 113245 ➤ Subscribe
Hungary 219599 ➤ Subscribe
Hungary 9904687 ➤ Subscribe
Hungary 227493 ➤ Subscribe
China 1088709 ➤ Subscribe
Czech Republic 9603214 ➤ Subscribe
Czech Republic 293455 ➤ Subscribe
Germany 10299001 ➤ Subscribe
Germany 69505296 ➤ Subscribe
Denmark 0680967 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Deloitte
Johnson and Johnson
Julphar
Fuji
Farmers Insurance
QuintilesIMS
Mallinckrodt
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot